The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Clinical benefit rate (CBR) of panitumumab monotherapy among patients with KRAS wild-type metastatic colorectal cancer (mCRC).
Hagen F. Kennecke
Consultant or Advisory Role - Amgen; Amgen; Bristol-Myers Squibb; Bristol-Myers Squibb
Honoraria - Amgen; Amgen; Bristol-Myers Squibb; Bristol-Myers Squibb
Research Funding - Amgen; Amgen; Bristol-Myers Squibb; Bristol-Myers Squibb
Howard John Lim
No relevant relationships to disclose
Balvindar Singh Johal
No relevant relationships to disclose
Muhammad Zulfiqar
No relevant relationships to disclose
Caroline Speers
No relevant relationships to disclose